Background. Over the years, the profile of patients with invasive pulmonary aspergillosis (IPA) has extended beyond the commonly associated population with hematologic malignancy (HM) and is now comprising patients with solid tumors and patients with lung diseases. We therefore aimed to compare the clinical characteristics, diagnostic approach and therapeutic outcome of IPA in cancer patients with hematologic malignancies vs. solid tumor (ST).
Methods. We conducted a retrospective study evaluating consecutive cases of proven and probable IPA from March 2004 to December 2016 in a tertiary cancer center. We included patients >18 years with an underlying ST, HM, or Hematopoietic Cell Transplantation (HCT) within 1 year of IPA diagnosis.
Results. A total of 311 patients were analyzed: 225 had HM including HCT and 86 ST. Patients with ST were more likely to have had COPD (33% vs. 8%, P > 0.01) or other underlying pulmonary diseases when compared with HM patients (76% vs. 43%, P < 0.01). Radiation therapy prior to the infection was also notably higher in the ST group than the HM group (48% vs. 14%, P < 0.01). Patients with HM were more likely to have received steroid (38% vs. 15%, P = 0.0001) and have concurrent neutropenia 37% vs. 2%, P < 0.0001). A. fumigatus was most commonly recovered in patients with ST than in patients with HM (66% vs. 38%, P < 0.01). Monotherapy and voriconazole-based primary antifungal therapy were more often prescribed in patients with ST than in patients with HM (87% vs. 56%, P < 0.0001 and 77% vs. 53%, P = 0.0002 respectively). Complete or partial successful response to therapy was recorded in 66% of patients with ST compared with 40% in the HM group (P = 0.0001). IPA attributable mortality within 12 weeks was significantly higher in the HM than in the ST group (30% vs. 18%, P = 0.04).
Conclusion. Monotherapy with voriconazole were more often prescribed in patients with ST than in patients with HM. Patients with ST had a better response to antifungal therapy and a lower IPA attributable mortality within 12 weeks compared with those with HM.
Disclosures. All authors: No reported disclosures. Background. Detection of β-D-glucan (BDG) in serum is recognized as the mycological evidence in the diagnosis of invasive fungal infection (IFI). However, its diagnostic value in low prevalence of IFI has not been elucidated. We aimed to examine the performance of BDG in hematology patients receiving antimold prophylaxis.
Low Positive Predictive Value of β-d-Glucan in Hematology Patients
Methods. We retrospectively reviewed all BDG results performed for the purpose of diagnosis or surveillance for IFI in hematology patients receiving posaconazole or micafungin prophylaxis from January 2017 to February 2019 in a tertiary hospital. At least two consecutive positive results of BDG were regarded as positive BDG. All the episodes were classified into true-positive (TP, positive BDG with probable/proven IFI), true-negative (TN, negative BDG without probable/proven IFI), false-positive (FP, positive BDG without probable/proven IFI), false-negative (FN, negative BDG with probable/proven IFI), and nonevaluable (could not be determined for the occurrence of breakthrough IFI). When BDG test was performed in the setting of persistent fever ≥72 hours in spite of broad-spectrum antibiotics or with a suspicion of IFI, it was defined as a diagnostic BDG episode, while others were defined as a surveillance BDG episode.
Results. Of a total of 140 episodes, 24 episodes were non-evaluable. Among 116 evaluable episodes, 75 received induction chemotherapy for acute leukemia or myelodysplastic syndrome, 35 underwent stem cell transplantation, and 10 had intensive treatment for graft-vs.-host disease. There were three episodes of probable/proven IFI (2.6%). Ninety-one (78.4%) were performed with diagnostic purpose, while 25 (21.6%) were performed for surveillance. TP, TN, FP, and FN were 2 (1.7%), 91, 22, and 1, respectively. Sensitivity, specificity, positive predictive value (PPV), and negative predictive value were 66.7%, 80.5%, 8.3% and 98.9%, respectively. PPV was 13.3% and 0% in diagnostic and surveillance BDG episodes, respectively.
Conclusion. The PPV of BDG was low in hematology patients receiving antimold prophylaxis, even in the diagnostic-driven episodes. The routine screening of BDG is not helpful, and the BDG test may be used for exclusion of IFI rather than for diagnosis in these patients.
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No reported disclosures. Background. Endemic mycoses are caused by the dimorphic fungi Histoplasma capsulatum, Blastomyces dermatitidis, and Coccidiodes species. Histoplasmosis and blastomycosis are endemic in Minnesota, with travel to coccidioidomycosis endemic areas being common. Diagnosis is challenging, in part due to confusion regarding laboratory testing. In our institution, we have observed that fungal serologies are often ordered when such infections are suspected, but results rarely seem to affect management. We reviewed the impact of serologic testing on the management of a Midwest veteran population.
Impact of Fungal Serologies in the Management of Veteran Patients with Suspected Endemic Mycoses

Methods.
Retrospective, observational study of patients with any serologic testing for endemic mycoses performed from January2014 to December 2018 at the Minneapolis VA Health Care System. To focus evaluation on the utility of serologic testing, we excluded patients with fungal antigen testing.
Results. Of 127 patients tested, 62 (49%) had only serologic testing. Patients were predominantly males (95%) with a median age of 66 years (range 27-93). Nineteen (31%) were tested in the hospital and had a median stay of 8 days (range 1-48). Median Charlson score was 4 (range 0-12). Travel to an endemic area for coccidioidomycosis was frequent (27/62: 44%), with Arizona being the most common destination (20/27: 74%). Median illness duration was 30 days (range 1-720). Respiratory symptoms predominated (43/62: 69%), followed by nonspecific (6/62: 10%), neurologic (5/62: 8%), and musculoskeletal (2/62: 3%) symptoms. Five (8%) were asymptomatic. Abnormal imaging was common, with 27/62 (44%) patients having an abnormal chest radiograph (consolidation 15%, nodules 11%, and interstitial pattern 8%), and 44/62 (71%) having abnormal CT findings (nodules 55%, ground glass opacities 18%, and consolidation 15%). Six patients (10%) had positive serology, but antifungals were started only in one case. Fungal serology results impacted management in 19/43 (44%) patients seen in clinic, but in 0/19 tested as inpatients (P < 0.001). The most common action (16/19: 84%) was to cease diagnostic workup (table) .
Conclusion. Fungal serologies can be useful in patients evaluated in clinic who present with respiratory symptoms, abnormal imaging, and potential fungal exposure. Testing in hospitalized patients appears to offer little benefit.
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No reported disclosures. Thursday, October 3, 2019: 12:15 PM Background. Histoplasmosis is a systemic mycosis with a wide range of clinical manifestations which represents a diagnostic challenge. It affects immunocompromised patients but also, previously healthy individuals that are exposed to a large inoculum of Histoplasma. The aim of our study was to describe the clinical presentation, epidemiologic features, laboratory/imaging findings and outcome of pediatric patients with histoplasmosis.
Delayed Diagnosis of Histoplasmosis in Pediatric Patients due to Atypical Clinical Presentations
Methods. a retrospective study including patients diagnosed as Histoplasmosis according to ICD-10 at a tertiary care center in Mexico City during 2009 to 2019. Clinical, epidemiological and laboratory/imaging data were gathered from each patient's clinical file.
Results. 5 patients with diagnosis of histoplasmosis were included; 2 patients were classified as proven with histopathologic confirmation, 2 patients as probable and 1 patient as possible according to the EORTC/MSG. The mean age of presentation was 7 years, 3/5 patients were male and 3/5 reported exposure to bats. Diagnosis was delayed by an average time of 6 months due to the variability of clinical presentations (progressive disseminated histoplasmosis, spinal histoplasmosis, cerebral histoplasmosis, intestinal histoplasmosis and mild acute pulmonary histoplasmosis). For the diagnosis, 1/5 had positive ELISA, 1/5 positive immunodiffusion (M band), 1/5 positive EIA in cerebrospinal fluid and 2/5 with histopathology findings that matched histoplasmosis. Pulmonary imaging with interstitial infiltrates in 4/5 and evidence of cavitation in one patient. Hemophagocytic syndrome was a complication in 1/5 and medullary syndrome was developed in the patient with spinal histoplasmosis which resolved with treatment. Liposomal amphotericin B was the treatment in 4/5, followed by itraconazole as the maintenance therapy.
Conclusion. This study shows variable clinical presentations of Histoplasmosis which resulted in an important delay in diagnosis. This study highlights the importance of diagnostic suspicion in both healthy children and immunocompromised patients, always taking into account epidemiological risks such as exposure to bats.
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